SCHEMBL28862512

SCHEMBL28862512

NCc1ccc(-c2cnn(C3COC3)c2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KIT P10721 1/20 0.48
▸ BRD4 O60885 2/20 0.43
▸ CREBBP Q92793 1/20 0.43
▸ MKNK1 Q9BUB5 2/20 0.43
▸ MKNK2 Q9HBH9 2/20 0.43
▸ EIF4E P06730 1/20 0.43
▸ ALOX5AP P20292 4/20 0.42
▸ HRH3 Q9Y5N1 1/20 0.41
▸ PIM1 P11309 2/20 0.40
▸ LRRK2 Q5S007 1/20 0.40
▸ JAK2 O60674 1/20 0.39
▸ ABL1 P00519 1/20 0.38
▸ PIK3CD O00329 1/20 0.38
▸ PIK3CA P42336 1/20 0.38
▸ PIK3CB P42338 1/20 0.38
▸ PI4KA P42356 1/20 0.38
▸ PIK3CG P48736 1/20 0.38
▸ PI4KB Q9UBF8 1/20 0.38
▸ PIM2 Q9P1W9 1/20 0.37
▸ CYP2A6 P11509 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28956713 0.86 PIK3CD (0.49) HRH3PIM1PIK3CDPIK3CAPIK3CB
SCHEMBL22918771 0.74 MKNK1 (0.38) KITBRD4CREBBPMKNK1MKNK2
SCHEMBL29614332 0.73 MKNK1 (0.47) KITBRD4CREBBPMKNK1MKNK2
SCHEMBL15729226 0.73 LOXL2 (0.52) MKNK1MKNK2HRH3PIM1LRRK2
SCHEMBL28862445 0.72 EIF4E (0.42) KITBRD4CREBBPMKNK1MKNK2
SCHEMBL17113554 0.71 LPL (0.47) KITBRD4CREBBPMKNK1MKNK2
Hydrochloric Acid SCHEMBL17091179 0.71 LOXL2 (0.51) MKNK1MKNK2HRH3PIM1LRRK2
SCHEMBL27378010 0.71 JAK2 (0.46) KITBRD4CREBBPMKNK1MKNK2
SCHEMBL24958712 0.70 BRD4 (0.45) KITBRD4CREBBPMKNK1MKNK2
SCHEMBL25589668 0.70 MKNK1 (0.53) KITBRD4MKNK1MKNK2EIF4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260109697-A1 4-(IMIDAZO[1,2-A]PYRIDIN-3-YL)-PYRIMIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2026-04-23 — — US disclosed
US-20220267320-A1 4-(IMIDAZO[1,2-A]PYRIDIN-3-YL)-PYRIMIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2022-08-25 — — US disclosed
EP-4003992-A1 4-(IMIDAZO[1,2-A]PYRIDIN-3-YL) -PYRIMIDINE DERIVATIVES Merck Patent GmbH (DE) 2022-06-01 — — EP disclosed
CN-114174293-A 4- (imidazo [1,2-a ] pyridin-3-yl) -pyrimidine derivatives 默克专利股份公司 2022-03-11 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260109697-A1 4-(IMIDAZO[1,2-A]PYRIDIN-3-YL)-PYRIMIDINE DERIVATIVES CHUK, CNKSR1, KIT KIT 3/4885BRD4 2115/4885CREBBP 3518/4885
US-20220267320-A1 4-(IMIDAZO[1,2-A]PYRIDIN-3-YL)-PYRIMIDINE DERIVATIVES NCOA3, NCOR1, NCOA4 KIT 273/4885BRD4 1137/4885CREBBP 2463/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback